TCGA-NC-A5HP-01A-11R-A26W-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- HEDGEHOG_SIGNALING+0.250
- MYOGENESIS+0.200
- G2M_CHECKPOINT+0.170
- UNFOLDED_PROTEIN_RESPONSE+0.170
- WNT_BETA_CATENIN_SIGNALING+0.170
- NOTCH_SIGNALING+0.150
- MITOTIC_SPINDLE+0.130
- APICAL_JUNCTION+0.070
- MYC_TARGETS_V2+0.070
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- ALLOGRAFT_REJECTION-0.540
- INTERFERON_GAMMA_RESPONSE-0.520
- IL6_JAK_STAT3_SIGNALING-0.480
- INFLAMMATORY_RESPONSE-0.460
- COMPLEMENT-0.400
- XENOBIOTIC_METABOLISM-0.380
- IL2_STAT5_SIGNALING-0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20130253.TNBC | — | E | 0.894 |
| 2 | 20ed86b0-2e3d-44ec-88cd-eac5486fe15c | — | — | 0.847 |
| 3 | SRR6013547 | — | cohortMD1 | 0.839 |
| 4 | TCGA-D8-A1XD-01A-11R-A14D-07 | — | B | 0.837 |
| 5 | a9e8922f-fd6c-412d-85f5-40f5ea9b5455 | — | — | 0.824 |
| 6 | 20100144.Her2HRpos | — | D | 0.824 |
| 7 | ERR2208903 | — | — | 0.818 |
| 8 | SRR5903551 | — | cohortA1 | 0.818 |
| 9 | C3N-02435 | — | cohortSQ1 | 0.817 |
| 10 | SRR5088886 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.070 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.040 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.030 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |